Mesoblast Ltd - Company Profile

Powered by

All the data and insights you need on Mesoblast Ltd in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Mesoblast Ltd Strategy Report

  • Understand Mesoblast Ltd position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Mesoblast Ltd: Overview

Select Item

Mesoblast Ltd (Mesoblast) is a regenerative medicine company that develops regenerative cell-based products. Its most advanced candidate remestemcel-L is in phase III trials under the brand name RYONCIL for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast is advancing rexlemestrocel for localized inflammatory diseases including advanced heart failure, end-stage ischemic heart failure, and MPc-06-ID (rexlemestrocel) for the treatment of chronic low back pain. The company employs its proprietary technology platform, to discover and treat cardiac diseases, and hematological diseases, mesenchymal lineage adult stem cells (MLCs), spine and musculoskeletal disorders and immune-mediated and inflammatory conditions. The company has operations in the US, Australia, and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.

 Gain a 360-degree view of Mesoblast Ltd and make more informed decisions for your business Gain a 360-degree view of Mesoblast Ltd and make more informed decisions for your business Find out more
Headquarters Australia
Address L 38 55 Collins St, Melbourne, Victoria, 3000
Website www.mesoblast.com
Telephone 61 3 96396036
No of Employees 83
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange MSB (ASX)
Revenue (2023) $7.5M -26.6% (2023 vs 2022)
EPS XYZ
Net Income (2023) XYZ 10.4% (2023 vs 2022)
Market Cap* $217.8M
Net Profit Margin (2023) XYZ -22.1% (2023 vs 2022)
* As of and is in US$
View Mesoblast Ltd financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Mesoblast Ltd premium industry data and analytics

60+

Clinical Trials

Determine Mesoblast Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Catalyst Calendar

Proactively evaluate Mesoblast Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Mesoblast Ltd’s relevant decision makers and contact details.

18+

Pipeline Drugs

Identify which of Mesoblast Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

7

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Mesoblast Ltd’s commercialized product portfolio to stay one step ahead of the market.

Products and Services

Products Brands
Pipeline Ryoncil
Remestemcel-L: Revascor
Steroid-Refractory Acute Graft Versus Host Disease (Children)
XYZ
XYZ
XYZ
Understand Mesoblast Ltd portfolio and identify potential areas for collaboration Understand Mesoblast Ltd portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In November, the company entered into an agreement with the Blood and Marrow Transplant Clinical Trials Network to develop a pivotal trial of Ryoncil (remestemcel-L) in the treatment of adults with steroid-refractory acute graft versus host disease.
2023 Regulatory Approval In February, the company secured an approval from the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies for Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration in combination with hyaluronic acid (HA) as delivery agent for injection into the lumbar disc.
2021 Plans/Strategy In December, the company announced its plans to conduct an additional US Phase 3 trial to support submissions for potential approval in both the US and EU.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Mesoblast Ltd CSL Ltd Acrux Ltd Genetic Technologies Ltd IDT Australia Ltd
Headquarters Australia Australia Australia Australia Australia
City Melbourne Melbourne Melbourne Melbourne Melbourne
State/Province Victoria Victoria Victoria Victoria Victoria
No. of Employees 83 32,065 43 60 156
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Silviu Itescu Managing Director; Chief Executive Officer; Director Executive Board 2011 -
Eric Rose, MD Director; Chief Medical Officer Executive Board 2022 -
Dagmar Rosa-Bjorkeson Chief Operating Officer Senior Management 2021 -
Andrew Chaponnel Chief Financial Officer - Interim Senior Management 2021 -
Joseph R. Swedish Chairman Non Executive Board 2019 -
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into Mesoblast Ltd key executives to enhance your sales strategy Gain insight into Mesoblast Ltd key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward